Malignant Peripheral Nerve Sheath Tumor Overview

Save information for later
Sign Up

Learn About Malignant Peripheral Nerve Sheath Tumor

What is the definition of Malignant Peripheral Nerve Sheath Tumor?
A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.
What are the alternative names for Malignant Peripheral Nerve Sheath Tumor?
  • Malignant peripheral nerve sheath tumor
  • MPNST
  • Malignant neurilemmoma
  • Malignant neurofibroma
  • Malignant schwannoma
  • Neurofibrosarcoma
  • Neurogenic sarcoma
Who are the top Malignant Peripheral Nerve Sheath Tumor Local Doctors?
Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. John E. Ready
Orthopedics
Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. John E. Ready
Orthopedics

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (2.9 mi)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Ready is an Orthopedics provider in Boston, Massachusetts. Dr. Ready and is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Bone Tumor, Ewing Sarcoma, Osteoarthritis, Hip Replacement, and Knee Replacement. Dr. Ready is currently accepting new patients.

Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology
Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Gregory Cote
Hematology Oncology | Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.8 mi)
617-724-0287
Languages Spoken:
English
Offers Telehealth

Gregory Cote is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cote and is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Chordoma, Epithelioid Sarcoma, Synovial Sarcoma, and Tissue Biopsy.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Edwin Choy
Hematology Oncology | Oncology
Advanced in Malignant Peripheral Nerve Sheath Tumor
Dr. Edwin Choy
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (0.8 mi)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Choy and is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Chordoma. Dr. Choy is currently accepting new patients.

View All Doctors
What are the latest Malignant Peripheral Nerve Sheath Tumor Clinical Trials?
A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors
A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

Summary: This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers

Match to trials
Find the right clinical trials for you in under a minute
Get started
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
Who is this study for: Patients with newly diagnosed malignant peripheral nerve sheath tumor
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1

Summary: The purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus ipilimumab prior to standard therapy (surgery, chemotherapy or radiation therapy) in patients with Neurofibromatosis Type 1 (NF1) and newly diagnosed pre-malignant and malignant peripheral nerve sheath tumors (MPNST) for whom surgery for resection of tumor is indicated.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center